Bemidji State students present groundwater research at National Conference
Jun. 8—BEMIDJI — Six students from Bemidji State University's School of Sustainability and Life Sciences traveled to Pittsburgh this spring to share original research at the National Conference on Undergraduate Research. The event was held April 6 — 9 at the David L. Lawrence Convention Center.
Four students presented poster projects focused on groundwater flow in the Shingobee River Watershed, a long-term research site near Akeley supported through a partnership between BSU and the University of Minnesota. The work is led by Dr. Miriam Rios-Sanchez, associate professor and graduate advisor.
Ashley Crowl and Jordyn Harvey presented findings on aquifer layers and hydraulic properties of glacial aquifers. Their work identified multiple shallow and deep layers made up of sand and gravel, with evidence of vertical water flow and connections to nearby lakes and rivers. Mikenna Pattrin also contributed to the project but did not attend the conference.
Sienna Houle and Parker Young presented research analyzing how aquifers respond to rainfall. Using 13 years of data, they found that both shallow and deep groundwater levels react to precipitation, though at different speeds and intensities. Their study confirmed that groundwater in the watershed flows toward Shingobee Lake.
Both projects are part of a broader research initiative led by Trevor Wozniak, a master's student in environmental science. His graduate work uses environmental isotopes to study groundwater age and support future water management. Wozniak also mentors undergraduate researchers and attended the event.
Also attending was Jerome Johnson, a BSU student scholar with the North Star STEM Alliance, who participated to explore STEM-related research and connect with peers.
Hosted annually, the
National Conference on Undergraduate Research
provides students with opportunities to present work, network with fellow researchers and explore academic and career pathways.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
23 minutes ago
- Medscape
Can New Combo Fill ‘Unmet Need' in R/R Hodgkin Lymphoma?
Acimtamig, a first-in-class CD30/CD16A bispecific innate cell engager (ICE), combined with an off-the-shelf cord-blood derived natural killer cell product (AlloNK), shows safety and efficacy in the treatment of patients with relapsed or refractory (R/R) classical Hodgkin lymphoma, who otherwise have poor prognoses. 'Acimtamig in combination with AlloNK shows promising efficacy with a well-managed safety profile with the potential to address an unmet need in patients with R/R Hodgkin lymphoma who have exhausted standard-of-care treatment options,' said first author Joseph Maakaron, MD, of the Division of Hematology, Oncology and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, in presenting the findings at the American Society of Clinical Oncology (ASCO) 2025 annual meeting in Chicago. Patients with classical Hodgkin lymphoma who relapse after standard-of-care treatments, including chemotherapy, brentuximab vedotin, and checkpoint inhibitors, have few remaining treatment options. Acimtamig has previously shown some efficacy as monotherapy in the treatment of Hodgkin lymphoma, and when further combined with an allogenic cord blood derived natural killer cell product, encouraging objective response rates were observed in a proof-of-concept study. To test the approach in a more rigorous multicenter trial, Maakaron and colleagues conducted the current open-label phase 2 LuminICE-203 trial, enrolling 24 patients with R/R Hodgkin lymphoma. For the study, the patients were treated in one of four cohorts investigating two doses of acimtamig (200 mg or 300 mg weekly flat dosing for 6 weeks) in combination with two dose levels of AlloNK after standard lymphodepletion of up to three cycles and followed by a randomized part using the Simon two-stage design. While the patients had a median age of 42.5 years, the range was wide, ranging from age 23 to 80 years, and 16 (67%) were men. About two thirds of patients (66.7%) had extranodal disease, and they had all been heavily pre-treated with brentuximab vedotin and programmed cell death protein 1 inhibitors, with a median of 4.5 prior lines of treatment, including previous stem cell transplant and CAR T cell therapy among 14 (58%) patients. 'The patients had essentially exhausted all standard-of-care therapy options,' Maakaron emphasized. As of the latest cut-off, the study achieved its primary end point of an objective response rate, with a rate of 88% among the patients, with 14 (58%) achieving complete responses. Across all four dose cohorts, clinically meaningful deep responses were seen, with 10 ongoing responses. A progression-free survival estimate of 61% was observed at 6 months. More robust maximum peaks were observed after the third infusion, which was presumed to be due to a steady state that had been achieved at that time, he added. The safety profile was consistent with previous reports, with the therapy combination being well tolerated. The most common treatment-related side effects were mild to moderate infusion-related reactions, occurring in 50% of patients. There were no cases of graft vs host disease or immune effector cell-associated neurotoxicity syndrome, and cytokine release syndrome (CRS) was reported in six patients shortly after infusion. All treatment-emergent adverse events including infusion-related reactions and CRS events were controlled with standard-of-care interventions and quickly resolved. There were no fatal treatment-emergent adverse events. 'Acimtamig with AlloNK may provide a safe, effective, and durable new therapeutic option for patients with R/R Hodgkin lymphoma, with a progression-free survival estimate of 61% at 6 months,' Maakaron said. 'These early results support the co-administration approach of acimtamig with an off-the-shelf, commercially scalable, allogenic, cryopreserved natural killer cell product in a multicenter setting,' he said. Study Shows Best Response Rates to Date Commenting on the findings at the meeting, Sarah C. Rutherford, MD, associate professor of clinical medicine at Weill Cornell Medicine in New York City, said the need for better treatment options for those who have relapsed after standard therapies is pressing. 'This is really an unmet need in the field,' she underscored. 'Novel treatments in R/R classic Hodgkin lymphoma after brentuximab vedotin, checkpoint inhibitors, and autologous transplant are limited, and most don't really work that well.' 'We tend to use single-agent chemotherapies, repeat checkpoint inhibitors, and radiation, but these patients really suffer because of that, and clinical trial options have been lacking.' Rutherford noted that, with the innovative combination, safety and tolerability were important concerns. 'I was really struck by the tolerability of this regimen, with only five patients having grade 3 and one [having] grade 4 treatment-emergent adverse events.' Furthermore, the response rates were impressive, she noted. 'These are the best response rates observed to date in the post-brentuximab vedotin and checkpoint inhibitor setting, and the toxicities appear manageable,' she said. 'I think it's going to be unlikely to be as widely adopted as checkpoint inhibitors because of the nature of the cellular therapy approach, but I do think this is a very promising agent,' Rutherford said. 'I think it's the current best available trial option, and in the future, some version of this could become a third-line therapy in this disease.'
Medscape
28 minutes ago
- Medscape
Lifestyle Changes Boost Medical Therapy for CAD
In patients with chronic stable coronary artery disease (CAD), integrating intensive lifestyle modifications and goal-directed medical therapy — while reserving revascularization for those with severely reduced coronary flow capacity — resulted in improvements in risk factor scores and better clinical outcomes. METHODOLOGY: Researchers in Texas conducted a single-center randomized trial to evaluate the efficacy of combining lifestyle modifications with aggressive medical therapy in patients with subclinical, suspected, or established CAD and factors that put them at a high risk for poor outcomes. Between 2009 and 2017, patients aged 40 years or older were randomly assigned to receive either comprehensive care (n = 513; mean age, 61 years; 67% men) or standard care (n = 515; mean age, 61 years; 69% men). After randomization, all patients underwent baseline stress-rest PET to quantify coronary flow capacity and accordingly defer or guide interventions. Comprehensive care involved intensive lifestyle counseling, regular review of PET results, and targeted steps toward prespecified risk factor goals. Patients also received frequent follow-ups and round-the-clock access to phone or email support. Those without severely reduced coronary flow capacity were managed without invasive interventions. Standard care involved no review of results or contact for support, and PET results were unblinded only for patients with severely reduced coronary flow capacity at a high risk for mortality to consider potential revascularization. The primary outcome was a change in the summed risk score of 16 individual risk factors over a 5-year follow-up period. Major adverse cardiac events, their components, and revascularization after 90 days were assessed as secondary outcomes. TAKEAWAY: At 5 years, patients receiving comprehensive care had a lower summed risk score than those receiving standard care (difference in 5-year change, -1.4; P < .0001), along with significant improvements in individual risk factors such as low-density lipoprotein, BMI, and blood pressure ( P < .01 for all). < .0001), along with significant improvements in individual risk factors such as low-density lipoprotein, BMI, and blood pressure ( < .01 for all). Over 11 years of extended follow-up, the comprehensive care group had 31.4% fewer major adverse cardiac events, 42.7% fewer deaths, 37% fewer deaths or myocardial infarction events, and 35.1% fewer revascularizations than the standard care group ( P < .05 for all). < .05 for all). Only 5.4% of patients underwent revascularization within 90 days, which was primarily guided by the severity of coronary flow capacity. IN PRACTICE: 'The randomized, controlled, blinded 5-year CENTURY trial demonstrates that participants for whom invasive coronary procedures were safely deferred based on [coronary flow capacity] by PET, integrated with comprehensive, intense lifestyle modifications, and aggressive medical treatment targeted to goals significantly improved all risk factor scores with significant reduction in all-cause mortality,' the researchers reported. 'Review of risk factor data, PET images, and frequent supportive participant contact with CENTURY [trial] research staff appeared to enhance adherence of the comprehensive compared with the standard care group,' they added. SOURCE: This study was led by K. Lance Gould, MD, of the University of Texas McGovern Medical School in Houston. It was published online on May 29, 2025, in European Heart Journal . LIMITATIONS: This study was conducted at a single center. About 23% of patients did not participate in the follow-up visits or PET scans. Blinding coronary artery calcium and myocardial perfusion images in patients receiving standard care might have been a source of bias. DISCLOSURES: This study received support from the Weatherhead PET Centre endowment at the University of Texas-Houston. One author reported receiving internal funding from the funding source and being an applicant for FDA-cleared K231731 PET software. One author reported serving as the principal investigator of a trial which receives support from a medical device company. Several authors reported donating any personal honoraria or waiving off their rights to royalties to avoid conflicts of interest.
Bloomberg
an hour ago
- Bloomberg
Crypto Billionaire Hires Neuralink Employees for Brain Startup
Coinbase Global Inc. co-founder Fred Ehrsam has become the latest Silicon Valley billionaire to jump into the brain-health business, with his startup hiring at least eight people who used to work at Elon Musk's Neuralink. Unlike Musk's company, which inserts a chip in the brain, Ehrsam's Nudge aims to build a consumer headset-like product using ultrasound technology that Ehrsam hopes will treat brain diseases, improve your mood and help you sleep with the push of a button.
